XML 14 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Operating Costs and Expenses:        
General and administrative $ 1,889,000 $ 2,302,000 $ 14,516,000 $ 5,702,000
Research and development 2,551,000 2,734,000 7,472,000 9,145,000
In-process research and development impairment 0 1,325,000   1,325,000
Goodwill impairment   1,526,000   5,594,000
Total Operating Costs and Expenses 4,440,000 7,887,000 21,988,000 21,766,000
Loss from Operations (4,440,000) (7,887,000) (21,988,000) (21,766,000)
Other Income/Expense:        
Foreign currency exchange (loss) gain 14,000 3,000 30,000 1,000
Interest income, net 65,000 158,000 215,000 559,000
Total Other Income 79,000 161,000 245,000 560,000
Net Loss (4,361,000) (7,726,000) (21,743,000) (21,206,000)
Net Loss Attributable to Common Stockholders $ (4,361,000) $ (7,726,000) $ (21,743,000) $ (21,206,000)
Net Loss Per Share - Basic (in dollars per share) $ (0.45) $ (6.81) $ (3.38) $ (24.47)
Net Loss Per Share - Dilutive (in dollars per share) $ (0.45) $ (6.81) $ (3.38) $ (24.47)
Weighted average number of shares outstanding during the period - Basic (in shares) 9,676,521 1,134,391 6,429,227 866,529
Weighted average number of shares outstanding during the period - Dilutive (in shares) 9,676,521 1,134,391 6,429,227 866,529
Net Loss $ (4,361,000) $ (7,726,000) $ (21,743,000) $ (21,206,000)
Gain (loss) on foreign currency translation (30,000) 821,000 1,941,000 80,000
Total comprehensive loss $ (4,391,000) $ (6,905,000) $ (19,802,000) $ (21,126,000)